Table 3:

Baseline Module Expression and Exacerbation Rates.

Cell Association	Module Annotation	Mepolizumab N=125		Placebo N = 124
		RR	p-value	RR	p-value
Eosinophil	T2 inflammation	1.10 (0.89-1.35)	0.36	1.25 (1.05-1.5)	0.015
Eosinophil	Eicosanoid metabolism	1.15 (0.84-1.57)	0.37	1.62 (1.21-2.2)	0.0012
Eosinophil	Cytoplasmic proteins	1.19 (0.77-1.82)	0.42	1.74 (1.21-2.52)	0.0027
Eosinophil and Epithelium	Activation, mucus secretion	1.29 (1.06-1.58)	0.014	1.20 (1.00-1.44)	0.039
Epithelium	Keratinization, tight junctions	1.32 (1.09-1.61)	0.0053	1.11 (0.90-1.39)	0.30
Epithelium	EGFR signaling cell-cell adhesion	1.34 (1.10-1.64)	0.0049	1.10 (0.90-1.36)	0.31
Epithelium	Cilia function, IL33 response	1.25 (1.04-1.51)	0.020	1.11 (0.92-1.33)	0.24
Epithelium	Extracellular matrix production	1.41 (1.12-1.77)	0.0035	1.06 (0.86-1.32)	0.58
Epithelium	TGFB/SMAD3 cell differentiation	1.36 (0.98-1.89)	0.077	1.04 (0.74-1.45)	0.83
Epithelium	Tissue kallikreins, IL23/IL17 axis	1.24 (1.02-1.51)	0.030	1.03 (0.81-1.31)	0.82
Neutrophil	Neutrophil chemotaxis	0.72 (0.51-1.02)	0.062	0.70 (0.51-0.94)	0.011
Neutrophil	Type 1 IFN regulation	0.76 (0.58-1.00)	0.050	0.74 (0.58-0.95)	0.0099

Shown are results of negative binomial regression of exacerbation number compared to baseline nasal lavage module expression on a log2 scale for each module depicted in Figure 2. Rate Ratios [RR] represent the estimated rate ratio for a one unit increase in log2 module expression (i.e. doubling of expression). Bolded values correspond to a p≤0.05. Modules are listed by their cell association and annotation. Further details about each module are in Table S4.